The cohort analyzed in this study might be too small for establishing the minimum required CD34+ cell dosage in “HLA mismatch ≤3/10, not KIR‐B/HLA‐C synergistic” cases; we, however, would like to point out that the lowest CD34+ cell dosage among such cases in the studied cohort was 0.17 × 105/kg (n = 1), and this patient (male, age 25.5, intermediate‐risk AML, not CR status at transplant) had not suffered from relapse or mortality at the time of loss of follow‐up (748 days post‐transplant). The gene discussed is HLA-C; the disease is acute myeloid leukemia.